Dianthus Therapeutics (DNTH) Accumulated Expenses (2017 - 2025)

Dianthus Therapeutics' Accumulated Expenses history runs 9 years deep, the most recent figure standing at $19.5 million for Q4 2025.

• In Q4 2025, Accumulated Expenses rose 48.78% year-over-year to $19.5 million; the TTM figure through Dec 2025 stood at $19.5 million (up 48.78% YoY), while the FY2025 annual figure was $19.5 million, up 48.78% from the prior year.
• Accumulated Expenses was $19.5 million for Q4 2025 at Dianthus Therapeutics, up from $16.0 million in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $19.5 million in Q4 2025 to a low of $1.6 million in Q1 2023.
• Historically, Accumulated Expenses has averaged $8.5 million across 5 years, with a median of $7.4 million in 2021.
• The sharpest annual moves came in 2023 and 2024: Accumulated Expenses slumped 75.55% in 2023, then surged 273.13% in 2024.
• A 5-year view of Accumulated Expenses shows it stood at $7.8 million in 2021, then retreated by 15.53% to $6.6 million in 2022, then slipped by 1.57% to $6.5 million in 2023, then soared by 101.01% to $13.1 million in 2024, then surged by 48.78% to $19.5 million in 2025.
• The last three Accumulated Expenses figures came in at $19.5 million (Q4 2025), $16.0 million (Q3 2025), and $14.0 million (Q2 2025), per Business Quant data.